Vaxcyte, Inc. PCVX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -30.6%-5.0pp | -25.6%-4.8pp | -20.8%+0.8pp | -21.7%-2.0pp | -19.7%+0.7pp | |
| Return on assets | -28.1%-4.6pp | -23.5%-4.0pp | -19.5%+0.8pp | -20.3%-1.7pp | -18.6%+0.2pp | |
| Return on invested capital | -37.6%-4.7pp | -32.9%-1.0pp | -31.9%+0.8pp | -32.7%-3.4pp | -29.3%+0.2pp | |
| Liquidity | ||||||
| Current ratio | 7.5×-0.4× | 7.9×-0.9× | 8.8×-2.3× | 11.1×-6.6× | 17.7×+4.9× | |
| Quick ratio | 7.5×-0.4× | 7.9×-0.9× | 8.8×-2.3× | 11.1×-6.6× | 17.7×+4.9× | |
| Cash ratio | 1.1×+0.2× | 0.9×-0.6× | 1.4×-0.6× | 2×-1.6× | 3.6×+0.8× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $21.48+8.8% | $19.73-7.1% | $21.24-5.9% | $22.58-4.3% | $23.58-13.0% | |
| Valuation | ||||||
| Market capitalization | $8.36B+38.5% | $6.04B+29.2% | $4.68B+6.3% | $4.4B-9.5% | $4.86B-52.3% | |
| Enterprise value | $8.22B+37.4% | $5.98B+33.6% | $4.48B+7.2% | $4.18B-9.2% | $4.6B-53.5% | |
| Price / book | 2.8×+0.5× | 2.2×+0.6× | 1.6×+0.2× | 1.4×-0.1× | 1.5×-1.6× | |
| Free cash flow yield | -9.3%+1.8pp | -11.1%+0.8pp | -11.9%-1.1pp | -10.8%-0.9pp | -9.9%-5.3pp | |
| Earnings yield | -11.3%+1.4pp | -12.7%+1.4pp | -14.1%-1.6pp | -12.4%-2.0pp | -10.5%-5.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Vaxcyte, Inc.'s ratios come from?
- Every ratio is computed from Vaxcyte, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.